News

FAMPYRA received Health Canada approval for the symptomatic improvement of walking in adult MS patients with walking disability. The approval of FAMPYRA was based on the results of

TTC will represent GNT exclusively in Japan in promoting its products and technologies in the area of new drug discovery for neurological and inflammatory diseases. The alliance with

The patent was initially set to expire in May 2026 and latter was granted a patent term adjustment that extends the expiry date to February 2028, the company

Clotamin is an over-the-counter multivitamin product designed for use by patients on Warfarin or other anticoagulants (blood thinners). Under terms of the agreement, DS Healthcare will evaluate the

The plan includes creation of Special Economic Zone and measures to be taken to attract companies into the state with the help of pharmacy colleges, chemists and druggists

The REGENX program consists of a NAV rAAV8 vector expressing a normal copy of the human low-density lipoprotein receptor (hLDLR) gene. The study, conducted at University of Pennsylvania

Carbonic anhydrase IX, or CAIX, is a transmembrane protein whose expression is restricted to few normal tissues. Under hypoxic conditions, hypoxia inducible factor-1 alpha (HIF-1a) is stabilized and

ColonSentry requires a small blood sample and utilizes RNA to measure the level of expression of seven specific genes. Enzo president Barry Weiner said ColonSentry recently received New

The trials evaluated blood levels of MoxDuo CR’s components to OxyContin and MS Contin and demonstrated MoxDuo CR’s superior results, with sustained blood levels for up to 24